Rennova Health, Inc. Granted 180 Day Extension by Nasdaq
14 9월 2016 - 9:30PM
Business Wire
Rennova Health, Inc. (NASDAQ:RNVA), (NASDAQ:RNVAZ), a
vertically integrated provider of industry-leading diagnostics and
supportive software solutions to healthcare providers, announced
today that on September 13, 2016, Nasdaq confirmed that the Company
had been granted an extension of 180 days to comply with rule
5550(a)(2) (“the Rule”), relating to the bid price of the Company’s
common stock not meeting the minimum $1.00 per share requirement
for continued listing.
Nasdaq staff determined that the Company was eligible for an
additional 180 calendar day period to regain compliance, based on
the Company meeting the continued listing requirement for the
market value of publicly held shares and all other applicable
requirements for initial listing on the Nasdaq Capital Market with
the exception of the bid price requirement, and the Company’s
written notice of its intention to cure the deficiency during the
second compliance period, including effecting a reverse stock split
if necessary.
If at any time before March 13, 2017, the bid price of the
Company's common stock closes at $1.00 per share or more for a
minimum of 10 consecutive business days, the Company will regain
compliance with the Rule, and the matter will be closed.
About Rennova Health, Inc.
Rennova Health provides industry-leading diagnostics and
supportive software solutions to healthcare providers, delivering
an efficient, effective patient experience and superior clinical
outcomes. Through an ever-expanding group of strategic brands that
work in unison to empower customers, we are creating the next
generation of healthcare. For more information, please visit
www.rennovahealth.com.
Forward-Looking Statements
This press release includes “forward-looking statements” within
the meaning of the safe harbor provisions of the United States
Private Securities Litigation Reform Act of 1995. Actual results
may differ from expectations and, consequently, you should not rely
on these forward-looking statements as predictions of future
events. Words such as “expect,” “estimate,” “project,” “budget,”
“forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,”
“should,” “believes,” “predicts,” “potential,” “continue,” and
similar expressions are intended to identify such forward-looking
statements. These forward-looking statements involve significant
risks and uncertainties that could cause the actual results to
differ materially from the expected results. Additional information
concerning these and other risk factors are contained in the
Company’s most recent filings with the Securities and Exchange
Commission. The Company cautions readers not to place undue
reliance upon any forward-looking statements, which speak only as
of the date made. The Company does not undertake or accept any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements to reflect any change
in their expectations or any change in events, conditions or
circumstances on which any such statement is based, except as
required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160914005385/en/
Rennova HealthSebastien Sainsbury,
561-666-9818ssainsbury@rennovahealth.comorInvestorsLHAKim Golodetz,
212-838-3777Kgolodetz@lhai.comorBruce Voss,
310-691-7100Bvoss@lhai.com
Rennova Health - Warrant (NASDAQ:RNVAZ)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Rennova Health - Warrant (NASDAQ:RNVAZ)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024